List of Tables

Table 2.1	Available antibody-based cancer treatments.	51
Table 3.1	Calibration curve of ATZ by HPLC at 215 nm, Data presented as Mean ± SD, n=3.	93
Table 3.2	Accuracy of ATZ measurement using mobile phase at 215 nm.	96
Table 3.3	Precision of ATZ measurement using mobile phase at 215 nm, Data presented as Mean, n=3.	96
Table 3.4	Calibration curve of EXE by HPLC at 247 nm, Data presented as Mean ± SD, n=3.	98
Table 3.5	Accuracy of EXE measurement using mobile phase at 247 nm.	99
Table 3.6	Precision of EXE measurement using mobile phase at 247 nm, Data presented as Mean, n=3.	99
Table 4.1	Selection of organic phase in preliminary optimization of ATZ loaded PLGA NPs	132
Table 4.2	Selection of volume of organic solvent in preliminary optimization of ATZ loaded PLGA NPs	133
Table 4.3	Selection of surfactant in preliminary optimization of ATZ loaded PLGA NPs	133
Table 4.4	Coded values of the formulation parameters of ATZ loaded PLGA NPs	134
Table 4.5	Layout of 3^3 full factorial design for ATZ loaded PLGA NPs	135
Table 4.6	Model coefficients estimated by multiple regression analysis for percentage drug entrapment of ATZ loaded PLGA NPs	136
Table 4.7	Model coefficients estimated by multiple regression analysis for particle size of ATZ loaded PLGA NPs	136
Table 4.8	Analysis of Variance (ANOVA) of full and reduced models for PDE of ATZ loaded PLGA NPs	137
Table 4.9	Analysis of Variance (ANOVA) of full and reduced models for PS of ATZ loaded PLGA NPs	137
Table 4.10	Check point analysis, t test analysis and normalized error determination	143

Table 4.11	Effect of cryoprotectants and their concentration on PS of lyophilized NPs after re-dispersion in distilled water	143
Table 4.12	Selection of organic phase in preliminary optimization of ATZ loaded cPCL NPs	144
Table 4.13	Selection of volume of organic solvent in preliminary optimization of ATZ loaded cPCL NPs	144
Table 4.14	Selection of surfactant in preliminary optimization of ATZ loaded cPCL NPs	145
Table 4.15	Coded values of the formulation parameters of ATZ loaded cPCL NPs	146
Table 4.16	Layout of 3^3 full factorial design for ATZ loaded cPCL NPs	147
Table 4.17	Model coefficients estimated by multiple regression analysis for percentage drug entrapment of ATZ loaded cPCL NPs	148
Table 4.18	Model coefficients estimated by multiple regression analysis for particle size of ATZ loaded cPCL NPs	148
Table 4.19	Analysis of Variance (ANOVA) of full and reduced models for PDE of ATZ loaded cPCL NPs	149
Table 4.20	Analysis of Variance (ANOVA) of full and reduced models for PS of ATZ loaded cPCL NPs	149
Table 4.21	Check point analysis, t test analysis and normalized error determination	154
Table 4.22	Effect of cryoprotectants and their concentration on PS of lyophilized NPs after re-dispersion in distilled water	155
Table 4.23	Selection of organic phase in preliminary optimization of EXE loaded PLGA NPs	156
Table 4.24	Selection of surfactant phase in preliminary optimization of EXE loaded PLGA NPs	156
Table 4.25	Selection of surfactant concentration in preliminary optimization of EXE loaded PLGA NPs	157
Table 4.26	Coded values of the formulation parameters of EXE loaded PLGA NPs	157
Table 4.27	Box Behnken experimental design with measured responses for EXE loaded PLGA NPs	158

Table 4.28	Model coefficients estimated by multiple regression analysis for PDE of EXE loaded PLGA NPs	159
Table 4.29	Model coefficients estimated by multiple regression analysis for PS of EXE loaded PLGA NPs	159
Table 4.30	Analysis of Variance (ANOVA) of full and reduced models for PDE of EXE loaded PLGA NPs	160
Table 4.31	Analysis of Variance (ANOVA) of full and reduced models for PS of EXE loaded PLGA NPs	161
Table 4.32	Check point analysis, t test analysis and normalized error determination	164
Table 4.33	Effect of cryoprotectants and their concentration on PS of lyophilized NPs after re-dispersion in distilled water	167
Table 4.34	Selection of organic phase in preliminary optimization of EXE loaded cPCL NPs	167
Table 4.35	Selection of surfactant in preliminary optimization of EXE loaded cPCL NPs	168
Table 4.36	Selection of surfactant concentration in preliminary optimization of EXE loaded cPCL NPs	168
Table 4.37	Coded values of the formulation parameters of EXE loaded cPCL NPs	169
Table 4.38	Box Behnken experimental design with measured responses for EXE loaded cPCL NPs	169
Table 4.39	Model coefficients estimated by multiple regression analysis for PDE of EXE loaded cPCL NPs	171
Table 4.40	Model coefficients estimated by multiple regression analysis for PS of EXE loaded cPCL NPs	171
Table 4.41	Analysis of Variance (ANOVA) of full and reduced models for PDE of EXE loaded cPCL NPs	172
Table 4.42	Analysis of Variance (ANOVA) of full and reduced models for PS of EXE loaded cPCL NPs	172
Table 4.43	Check point analysis, t test analysis and normalized error determination	178
Table 4.44	Effect of cryoprotectants and their concentration on PS of	178

	lyophilized NPs after re-dispersion in distilled water	
Table 4.45	Stability data of ATZ loaded PLGA NPs stored at different temperature conditions	183
Table 4.46	Stability data of ATZ loaded cPCL NPs stored at different temperature conditions	188
Table 4.47	Stability data of EXE loaded PLGA NPs stored at different temperature conditions	193
Table 4.48	Stability data of EXE loaded cPCL NPs stored at different temperature conditions	198
Table 5.1	Physicochemical characterization of ATZ loaded PLGA NPs, pegylated PLGA NPs and ImmunoNPs	210
Table 5.2	Physicochemical characterization of EXE loaded cPCL NPs, pegylated PCL NPs and ImmunoNPs	215
Table 6.1	Intracellular uptake of 6-Coumarin loaded PLGA NPs, pegylated PLGA NPs and ER antibody conjugated ImmunoNPs by MCF7 cells using flow cytometry. Uptake was calculated by measuring MFI and represented as mean ± S.D. (n=3)	230
Table 6.2	Intracellular uptake of 6-Coumarin loaded PCL NPs, pegylated PCL NPs and ER antibody conjugated ImmunoNPs by MCF7 cells using flow cytometry. Uptake was calculated by measuring MFI and represented as mean ± S.D. (n=3)	231
Table 6.3	Cytotoxicity of formulations loaded with ATZ and tested on MCF7 cell line	236
Table 6.4	Cytotoxicity of formulations loaded with EXE and tested on MCF7 cell line	238
Table 6.5	Apoptosis studies in MCF7 cell line after treatment of (a) Control (PBS), (b) ATZ solution, ATZ loaded (c) PLGA, (d) PLGA-PEG NPs and (d) PLGA-PEG ImmunoNPs using FACS technique.	241
Table 6.6	Apoptosis studies in MCF7 cell line after treatment of (a) Control (PBS), (b) ATZ solution, ATZ loaded (c) PCL, (d) PCL-PEG NPs and (d) PCL-PEG ImmunoNPs using FACS	241

technique.

Table 6.7 Apoptosis studies in MCF7 cell line after treatment of (a) Control (PBS), (b) EXE solution, EXE loaded (c) PLGA, (d) PLGA-PEG NPs and (d) PLGA-PEG ImmunoNPs using FACS technique. 242

Table 6.8 Apoptosis studies in MCF7 cell line after treatment of (a) Control (PBS), (b) EXE solution, EXE loaded (c) PCL, (d) PCL-PEG NPs and (d) PCL-PEG ImmunoNPs using FACS technique. 242

Table 6.9 Cell cycle analysis in MCF7 cell line after treatment of (a) Control (PBS), (b) ATZ solution, ATZ loaded (c) PLGA-PEG NPs and (d) PLGA-PEG ImmunoNPs by PI staining using FACS technique. 248

Table 6.10 Cell cycle analysis in MCF7 cell line after treatment of (a) Control (PBS), (b) ATZ solution, ATZ loaded (c) PCL-PEG NPs and (d) PCL-PEG ImmunoNPs by PI staining using FACS technique. 249

Table 6.11 Cell cycle analysis in MCF7 cell line after treatment of (a) Control (PBS), (b) EXE solution, EXE loaded (c) PLGA-PEG NPs and (d) PLGA-PEG ImmunoNPs by PI staining using FACS technique. 250

Table 6.12 Cell cycle analysis in MCF7 cell line after treatment of (a) Control (PBS), (b) EXE solution, EXE loaded (c) PCL-PEG NPs and (d) PCL-PEG ImmunoNPs by PI staining using FACS technique. 251

Table 7.1 Approximate half life of various radioisotopes. 255

Table 7.2 Stability of iodinated complexes after 24 h. 259

Table 7.3 Biodistribution of ^{125}I labeled Tyrosine and ER antibody conjugated PLGA NPs and the radioactivity was measured after 3 and 24 h post injection. The values represented as mean ± SD. Radioactivity is expressed as percent of administered dose per gram of tissue or organ. 260

Table 7.4 Different ratio between the tissue/organ of ^{125}I labeled Tyrosine 261

and ER antibody conjugated PLGA NPs.

Table 7.5 Biodistribution of ^{125}I labeled Tyrosine and ER antibody conjugated PCL NPs and the radioactivity was measured after 3 and 24 h post injection. The values represented as mean ± SD. Radioactivity is expressed as percent of administered dose per gram of tissue or organ. 262

Table 7.6 Different ratio between the tissue/organ of ^{125}I labeled Tyrosine and ER antibody conjugated PCL NPs. 263